Pharmafile Logo
Pharmafocus logo
Advanced Search
amgen_hq

Amgen’s Kyprolis disappoints in Phase III trial

September 27, 2016
Manufacturing and Production, Research and Development Amgen, Kyprolis, phase III

Amgen was relying on the results of the trial to justify its $10.4 billion purchase of Onyx Pharmaceuticals, acquiring Kyprolis …

News
cancer-389921_960_720

Kite Pharma flying high after promising Car-T trial

September 27, 2016
Manufacturing and Production, Research and Development Cancer, Cart-T, kite pharma

Cart-T cell drugs are made by genetically altering patients’ T-cells to add a component of antibodies that make them better …

News
heather_bresch_2

Price-hiked EpiPen profits 66% higher than Mylan CEO claimed

September 27, 2016
Business Services, Manufacturing and Production, Sales and Marketing Heather Bresch, Mylan, epipen

In the latest development in the Mylan EpiPen scandal, it has been discovered that CEO Heather Bresch lied to US …

News

Sanofi secures $43 million government funding for zika vaccine development

September 27, 2016
Manufacturing and Production, Research and Development BARDA, Sanofi, Zika

The US Department of Health and Human Services approved $43.18 million to fund Sanofi’s development of a zika vaccine, the …

News
jj_2johnson_and_johnson

Johnson & Johnson’s Stelara receives FDA approval

September 27, 2016
Manufacturing and Production, Research and Development Janssen Biotech, Johnson & Johnson, Stelara

The drug is approved for use to treat the skin condition scaly plaque psoriasis and a type of arthritis associated …

News
biogen_austria_238

Biogen closes in on bringing muscular atrophy preventing drug to market

September 26, 2016
Manufacturing and Production, Research and Development Biogen, EMA, FDA, Nusinersen

Biogen has applied for Priority Review, which, if granted, would shorten the review period necessary for nusinersen. They also plan …

News

CPHI Worldwide: PCI to Share Expertise in Serialization and Safe Handling of Potent Molecules

September 26, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CPhI

Leading pharmaceutical provider PCI Pharma Services will bring its expertise to the stage at CPHI Worldwide (Barcelona, October 4-6 2016) …

News
Press release

Pfizer decides not to break up business

September 26, 2016
Sales and Marketing Ian Read, Pfizer, United States, america

In the intervening four years, Pfizer has conducted “extensive evaluation” into the possibility, with the company reorganising into two distinct …

News
australian-flag-map_zps69235009

Australian pharmaceutical market to grow to be worth $25 billion by 2020

September 26, 2016
Business Services, Sales and Marketing Australia, Australian Government

The Australian market, in 2016, is currently worth over $22.85 billion and is predicted to reach $25.2 billion by 2020, …

News
fda2outsideweb

Sanofi and Regeneron’s atopic dermatitis drug secures FDA priority review

September 26, 2016
Research and Development, Sales and Marketing

Regeneron and Sanofi have announced that the US Food and Drug Administration has granted priority review for the pair’s atopic …

News

Merck elects Isabel De Paoli as CSO

September 26, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck, appointment

German pharma firm Merck has appointed Isabel De Paoli to the position of chief science officer in addition to her …

News

Woodley Equipment Company to Attend ICSE Exhibition, Barcelona

September 26, 2016
Clinical Trials Supplier, medical and laboratory equipment provider

Woodley Equipment is attending ICSE Exhibition taking place on 4th to 6th October 2016 at Fira de Barcelona Gran Via, Barcelona, Spain. 

News
Press release
humira_abbott__4

FDA gives the green light to the first Humira biosimilar

September 26, 2016
Sales and Marketing AbbVie, Amgen, Amjevita, FDA, Humira

Amgen’s Amjevita has been given the go ahead for all eligible indications of its reference product, including moderate-to-severe rheumatoid arthritis, …

News

NICE approval for restricted-use hypophosphatasia therapy

September 23, 2016
Medical Communications, Sales and Marketing Alexion Pharmaceuticals, Strensiq, hypophosphatasia

The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of Alexion Pharmaceutical’s Strensiq …

News
4420456374_64a3d7e6aa

Top ten stories in the pharmaceutical industry this week

September 23, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing top ten

It’s Friday (and print day for the Pharmafocus October edition!) and its been a pretty explosive week, from new and …

News
alzheimers_brain

Alzheimer’s drug failure sends Lundbeck’s shares crashing

September 23, 2016
Medical Communications, Research and Development Alzheimer's, Lundbeck, cultural failings

Lundbeck’s experimental idalopirdine has failed to meet its primary endpoint in its first Phase III trial in the treatment of …

News
novo_nordisk_flag

Novo Nordisk to provide discounted insulin to poorest nations

September 23, 2016
Medical Communications, Sales and Marketing Novo Nordisk, diabetes, insulin

Danish pharma firm Novo Nordisk has announced its intention to provide insulin at discounted prices to the world’s poorest nations …

News
shutterstock_232245868

Novartis’ Zykadia smashes Phase III target for lung cancer

September 23, 2016
Medical Communications, Research and Development Novartis, lung cancer, zykadia

Novartis has announced that its cancer drug Zykadia (ceritinib) has achieved positive results in its Phase III clinical trial investigating …

News
shutterstock_359806121

DNA damage response biotech launches with £25m funding

September 22, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, dna damage response, funding

Cambridge-based Artios Pharma has officially launched after raising £25 million in series A financing from US and European life science …

News
un_assembly

193 countries sign UN declaration to fight drug-resistant infection

September 22, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Jeremy Hunt, UN, drug-resistant infection

A historic UN declaration to fight drug-resistant infection across the globe has been signed by 193 countries at the United …

News
The Gateway to Local Adoption Series

Latest content

Ofichem brings all brands under single trading name

April 23, 2026

Carvolix strengthens its Board of Directors, advisory board and governance structure

April 23, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

April 22, 2026

Incyclix Bio announces new additions to the Board

April 22, 2026

Remedy Plan Therapeutics Appoints Jotin Marango as CFO and CBO

April 21, 2026